Q-omics provides the consensus-scored GRHL1 profile across patient tissues and cancer cell-line models. GRHL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GRHL1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, GRHL1 RNA expression shows 19,162 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where GRHL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRHL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRHL1 survival associations across molecular data types. GRHL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRHL1 RNA expression–survival associations across cancer types. High GRHL1 expression shows unfavorable associations in UVM, BRCA, MESO and LIHC, but favorable associations in LUSC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for GRHL1 RNA expression.
This table summarizes GRHL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GRHL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRHL1 shows lower tumor expression in KIRC and HNSC and higher tumor expression in COAD, LUSC, LUAD and BLCA. The COAD box plot shows higher GRHL1 RNA expression in tumor versus normal tissue (log2 FC = +1.307, t-test p < 0.001).
This table shows molecular features associated with GRHL1 in patient tissues and cancer cell lines. In patient samples, GRHL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRHL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
